Immunohistochemical detection of Her-2/neu overexpression in breast carcinoma in Nigerians: A 5-year retrospective study

Nigerian Journal of Clinical Practice

Volumn 14, Issue 3, 2011, Pages 332-337

  Ugiagbe, E E ^a   Olu Eddo, A N ^a   Obaseki, D E ^a  

^a UNIVERSITY OF BENIN   (Nigeria)

Author keywords

Breast cancer; Her 2 neu; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; ANIMAL; ARTICLE; BREAST TUMOR; CANCER GRADING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; NIGERIA; PROGNOSIS; RABBIT; RETROSPECTIVE STUDY; TEACHING HOSPITAL;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANIMALS; BREAST NEOPLASMS; FEMALE; HOSPITALS, TEACHING; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NIGERIA; PROGNOSIS; RABBITS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84855253599     PISSN: 11193077     EISSN: None     Source Type: Journal    
DOI: 10.4103/1119-3077.86779     Document Type: Article

References (25)

1. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet 2005;365:1727-41. (Pubitemid 40719108)
2. Adebamowo CA, Ogundiran TO, Adenipekun AA, Oyesegun RA, Campbell OB, Akang EE, et al. Waist-hip ratio and breast cancer risk in urbanized Nigerian women. Breast Cancer Res 2003;5:R18-23.
3. Prati R, Apple SK, He J, Gornbein JA, Chang HR. Histopathologic characteristics predicting Her-2/neu Amplification in Breast Cancer. Breast J 2005;11:433-9. (Pubitemid 41743418)
4. Yamauchi H, Stearns V, Hayes DF. When is a tumour marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-56. (Pubitemid 32366985)
5. Tawfik OW, Kimler BF, Davis M, Danahue JK, Persons DL, Fan F, et al. Comparison of immunohistochemistry by automated cellular imaging system (ACIS). Versus fluorescence in-situ hybridization in the evaluation of Her-2/ neu expression in primary breast carcinoma. Histopathology 2006;48:258-67.
6. Konecny G, Pauletti G, Pegram M, Untch M Dandekar S, Aguilar Z, et al. Quantitative association between Her-2/neu and steroid receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-53. (Pubitemid 36193263)
7. Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, et al. Comparison of methods of measuring Her-2/neu in metastatic breast cancer patients treated with high dose chemotherapy. J Clin Oncol 2001;19:1698-706. (Pubitemid 32230870)
8. Huang HJ, Neven P, Paridaens R, Amant F, Wildiers H, Berteloot F, et al. Association between tumour characteristics and Her-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005;58:611-8.
9. Burstein HJ. The distinctive nature of Her-2/neu positive breast cancers. N Engl J Med 2005;355:1652-4. (Pubitemid 41464703)
10. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Levine MN, et al. Her-2/neu and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-11. (Pubitemid 43736610)
11. World Health Organization. Pathology and genetics: Tumours of the breast and female genital organs. In: Tavassoli FA, Devilee P, editors. IARC Press; 2003. p. 10.
12. Breast In Rosai and Ackerman's Surgical Pathology, 9th Ed. CV Mosby Company; 2004. p. 1763-876.
13. Adesunkanmi AR, Lawal OO, Adelusola KA, Durosimi MA. The severity, outcome and challenges of breast cancer in Nigeria. Breast J 2006;15:399-409. (Pubitemid 43812214)
14. Francis GD, Dimech M, Giles L, Hopkins A. Frequency and reliability of oestrogen receptor, progesterone receptor and Her-2/neu in breast carcinoma determined by immunohistochemistry in Australasia: Result of the RCPA quality assurance programme. J Clin Pathol 2007;60:1277-83. (Pubitemid 350084552)
15. Jones BA, Kasi SV, Howe CL, Lachman M, Dubrow R, Curnen MM, et al. African- American/ White differences in breast carcinoma. Cancer 2004;101:1293-301.
16. Titiloye W. Histological pattern of epithelial breast cancer in Ile-Ife (OAUTH). A dissertation submitted to the National Postgraduate Medical College of Nigeria. May. 2008.
17. Adeoye AO. Histological and immunohistochemical patterns of breast cancer at the University College Hospital, Ibadan. A dissertation submitted to the West African College of Physicians. Oct 2007.
18. Gukes ID, Jenings BA, Mandong BM, Igun GO, Girling AC, Manasseh AN, et al. Clinicopathological features and molecular markers of breast cancer in Jos Nigeria. West Afr J Med 2005;24:209-13.
19. Rosen PP, Lesser ML, Arroyo CD, Crano M, Borgen P, Norton L. Immunohistochemical detection of Her-2/neu in patients with axillary lymph node negative breast carcinoma. Cancer 1995;75:1320-526.
20. Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, et al. Neu-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in Stage II breast cancer. N Engl J Med 1988;319:1239-45. (Pubitemid 18267063)
21. Marx D, Schauer A, Reiche C, May A, Ummemhofer L, Reles A, et al. C-erbB2 expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 1990;116:15-20. (Pubitemid 20132848)
22. Yamauchi H, Stearns V, Hayes DF. When is a tumour marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-56. (Pubitemid 32366985)
23. Burstein HJ. The distinctive nature of Her-2/neu positive breast cancers. N Engl J Med 2005;355:1652-4. (Pubitemid 41464703)
24. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Levine MN, et al. Her-2/neu and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-11. (Pubitemid 43736610)
25. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugano S, Watanabe S, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. Cancer 1990;65:1794-800. (Pubitemid 20116652)